For example, in patients who have favorable tumor characteristics (ER-positive/PR-positive, HER2-negative, and without nodal involvement) who met established guidelines for the recommendation of chemotherapy, those with favorable gene-expression profile may benefit from endocrine therapy alone33. The gene discussed is ERBB2; the disease is neoplasm.